The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...

Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...

Rare disease and gene therapy stocks, battered in recent months by clinical and commercial setbacks, will likely benefit from the sudden departure this past week of Vinayak (Vinay) Prasad, MD, as ...

Loomer had slammed Prasad for allegedly denying drug approvals for rare diseases, and for his past support of left-leaning figures like Senator Bernie Sanders ...

WASHINGTON, DC – Dr. Vinay Prasad, the polarizing official who led U.S. vaccine oversight under the Trump administration, has ...

This week on "The Readout LOUD," STAT's biotech reporters parse what Vinay Prasad's ouster means for biotech and the FDA.

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.

The U.S. Food and Drug Administration's top official, Vinay Prasad, has left the agency after nearly three months as Director ...

Dr. Vinay Prasad, the controversial critic of the US Food and Drug Administration who took a top role at the regulatory ...

The Food and Drug Administration's polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of ...

It is hard to imagine someone more equipped and more dedicated to vetting treatments than Vinay Prasad,” writes his former ...

The gene therapy chief wanted to block fast-track drug approvals.